文献速递类风湿关节炎

类风湿关节炎患者中JAK抑制剂或托珠单抗与TNF抑制剂的心血管安全性比较:随机临床试验的系统评价及传统与贝叶斯网络荟萃分析

Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.
PubMed 文献 · Semin Arthritis Rheum · 2024-10-02

该系统评价与网络荟萃分析纳入18项随机对照试验共21432例类风湿关节炎患者、57040患者年,比较JAK抑制剂或托珠单抗与TNF抑制剂的主要不良心血管事件(MACE)和全因死亡风险。传统荟萃分析中JAK抑制剂与TNF抑制剂相比MACE和全因死亡风险未达统计学显著升高(OR 1.232,95%CI 0.86-1.76;OR 1.3903,95%CI 0.94-2.07),贝叶斯分析显示JAK抑制剂组MACE和全因死亡增加15%以上的后验概率分别为61%和84%;托珠单抗与TNF抑制剂在两种分析中均无统计学差异。

要点

  • JAK抑制剂较TNF抑制剂的MACE风险OR 1.232(95%CI 0.86-1.76,p=0.56),未达统计学显著。
  • JAK抑制剂较TNF抑制剂的全因死亡OR 1.3903(95%CI 0.94-2.07,p=0.10),未达统计学显著。
  • 贝叶斯分析示JAK抑制剂组MACE和全因死亡增加≥15%的后验概率分别为61%和84%,托珠单抗组分别为11%和25%。

核心结论

  • 传统荟萃分析中JAK抑制剂与TNF抑制剂相比MACE和全因死亡风险未达统计学显著升高,但贝叶斯分析显示JAK抑制剂组MACE和全因死亡增加≥15%的后验概率较高。
  • 托珠单抗与TNF抑制剂在传统和贝叶斯分析中均无统计学差异,贝叶斯分析示托珠单抗组MACE和全因死亡临床相关差异的后验概率低。
  • 作者指出这些数据强化了监管机构和风湿病学会关于类风湿关节炎中使用JAK抑制剂的推荐,但尤其呼吁开展更多以主要安全性结局为目标的直接比较研究。

研究设计与样本

  • 系统评价6个医学数据库至2024年5月,纳入评估类风湿关节炎患者使用托珠单抗或JAK抑制剂(干预组)与对照(TNF抑制剂或安慰剂)比较的2-4期随机对照试验。
  • 由3名研究者独立评估研究数据,采用Cochrane协作工具评估偏倚风险。
  • 采用随机效应网络荟萃分析评估与TNF抑制剂相比的MACE(主要结局)和全因死亡(次要结局)风险。
  • 根据贝叶斯定理计算主要和次要结局增加15%以上的后验概率(PP15%)。
  • 共纳入18项随机对照试验,21432例患者,57040患者年。

主要发现

  • JAK抑制剂与TNF抑制剂相比,MACE风险OR 1.232(95%CI 0.86-1.76;p=0.56),全因死亡OR 1.3903(95%CI 0.94-2.07;p=0.10),均未达统计学显著。
  • 贝叶斯分析显示JAK抑制剂组较TNF抑制剂组MACE增加≥15%的后验概率(PP15%)为61%,全因死亡PP15%为84%。
  • 传统荟萃分析中托珠单抗与TNF抑制剂相比MACE的OR 1.029(95%CI 0.75-1.40;p=0.86),全因死亡OR 1.072(95%CI 0.78-1.48;p=0.67),均无统计学差异。
  • 贝叶斯分析中托珠单抗组MACE的PP15%为11%,全因死亡PP15%为25%,临床相关差异的后验概率低。

局限性

  • 本研究的主要局限性是除托法替布外JAK抑制剂的事件数少,反映了ORAL SURVEILLANCE的重要性。
  • 作者指出JAK抑制剂可用的结局数据仍然少且异质性大,呼吁开展更多以主要安全性结局为目标的直接比较研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to compare the risk of major adverse cardiovascular events (MACE) and all-cause of death (ACD) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi) or tocilizumab (TCZ) versus tumor necrosis factor (TNF) inhibitors (TNFi). METHODS: We performed a systematic review of six medical databases until May, 2024 for phase 2-4 randomized controlled trials (RCTs) evaluating patients with RA treated with TCZ or JAKi (intervention arm) compared with controls (TNFi or placebo). The study data were independently assessed by 3 investigators. The risk of bias was assessed using the Cochrane Collaboration tool. We performed a network meta-analysis with random effects to evaluate the risk of MACE (primary outcome) and ACD (secondary outcome) compared to TNFi. We also calculated the posterior probability of increasing the primary and secondary outcomes by 15% or more (PP15%) following Bayes' theorem. RESULTS: This meta-analysis included 18 RCTs with 21,432 patients and 57,040 patient-years. JAKi were linked to a non-statistically significant increase in the risk of MACE and ACD as compared to TNFi (ORs of 1.232 [95%CI 0.86-1.76]; p = 0.56 and ORs = 1.3903[95%CI 0.94-2.07]; p = 0.10, respectively). By Bayesian analysis, a high clinical probability of more frequent MACE (PP15% of 61%) and ACD (PP15% of 84%) was found in the JAKi group than in the TNFi group. No statistical difference was found between TCZ and TNFi in relation to MACE (1.029 [95%CI 0.75 -1.40]; p = 0.86) and ACD (1.072 [95%CI 0.78-1.48]; p = 0.67]) in the traditional meta-analysis. In the Bayesian approach, the probability of a difference in clinical relevance was low (PP15% for MACE of 11% and PP15% for ACD of 25%). DISCUSSION: The main limitation of this study is the small number of events with JAKi other than tofacitinib, reflecting the importance of ORAL SURVEILLANCE. Despite this, these data reinforce the recommendations of regulatory agencies and rheumatology societies on the use of JAKi in the context of RA, but above all call for more direct comparison studies involving primary safety outcomes with JAKi, since the outcome data available are still small and heterogeneous. In both meta-analyses, no difference was found between TNFi and TCZ.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Pugliesi A, Oliveira DGC, Filho VAS, et al. Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials. Semin Arthritis Rheum. 2024. PMID: 39383617. doi:10.1016/j.semarthrit.2024.152563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。